Item 8.01. Other Events
On
The presentation highlights certain data, including a successful completion of a toxicology study, which further supports the platform's flexible production capabilities allowing for highly scalable antigen production with the ability to rapidly address emerging infectious diseases, including COVID-19 variants of concern.
Dyadic's C1 technology has demonstrated the ability to rapidly develop Alpha, Beta, Gamma and Delta antigens alone or in various combinations from a single C1-cell line, which has broad global implications, for countries who currently lack an efficient vaccine manufacturing and distribution infrastructure. The presentation also discusses the initiation of development of a COVID-19 antigen against the emerging Omicron variant of concern.
Representatives of Dyadic will use the presentation in industry conferences, investor conferences and investor meetings from time to time. A copy of the presentation is also attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits (d) Exhibits The following exhibit is being furnished herein: Exhibit Number Description 99.1 Dyadic International Presentation, "C1 Technology Platform: Rapid response to Pandemic and other biological threats - Support the global combat against SARS-CoV-2 Variants of Concern", datedNovember 29, 2021 104 Cover page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source